Current partner codePEPTIDESDE
NCT07431957·Phase 4·INTERVENTIONAL

"Efficacy and Safety of Linaclotide in Chronic Constipation"

Status

Not yet recruiting

Phase

Phase 4

Enrollment

90

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Goal of this study is to evaluate the efficacy and safety of two different doses of Linaclotide in improving bowel function and patient-reported outcomes among Bangladeshi patients with chronic constipation for 8 weeks along with an additional short drug-free follow up period of 2 weeks. The main question it aims to answer is "Does Linaclotide at doses of 72microgram or 145microgram once daily improve bowel function and patient-reported coutcomes compared with placebo in Bangladeshi patients with chronic constipation over an 8-week treatment period?" Study procedure: From outpatient department of Gastroenterology, Dhaka Medical College, a total of 90 adult patients diagnosed with chronic idiopathic constipation (CIC) or constipation predominant irritable bowel syndrome (IBS-C) by ROME-IV criteria will be selected after baseline evaluation including clinical history, physical examination, laboratory tests and colonoscopy. Before enrollment eligible participants will undergo 1-week baseline stool diary which will include baseline data of patient reported severity of abdominal symptoms (bowel movement, stool frequency, bloating, abdominal pain or discomfort and defecatory satisfaction score). Patients reporting more than 3 SBMs during baseline run in period will be excluded from the study. Finally total 90 patients will be enrolled as participants who will be randomly assigned to one of the three groups, Group A (Linaclotide 72mcg once daily), Group B (Linaclotide 145mcg once daily) and Group C (Placebo once daily ). The treatment period will start from randomization visit (day 0) and will be continued for 8 weeks. All participants will receive identical looking drugs (72mcg or 145mcg or placebo) 30 minutes before breakfast and they will be requested to maintain standard dietary and lifestyle advices including increased intake of high fiber diet and fluid throughout the study. Patients will record spontaneous bowel movement (SBM) and complete spontaneous bowel movement (CSBM), stool consistency using Bristol Stool Form Scale (BSFS), severity of abdominal symptoms by 5-point Likert scale, use of rescue medication after 3 days of absolute constipation and adverse events such as diarrhea in their daily stool diary. They will be followed up at week-4, week-8 and after 2-week drug free withdrawal period at week-10 with review of stool diary and safety assessments. Entire study will be monitored by Data Safety Monitoring Board (DSMB) of Dhaka Medical College.

Interventions

Treatment arms and agents.

DRUG

Linaclotide 72 micrograms

Linaclotide 72 micrograms will be given in Group A

DRUG

Linaclotide 145 micrograms

Linaclotide 145 micrograms will be given in Group B

OTHER

Placebo

Placebo will be given in Group C

Timeline

From registration to results.

  1. First posted

    Feb 25, 2026

  2. Study start

    Feb 20, 2026

  3. Primary completion

    Dec 31, 2026

  4. Study completion

    Jan 31, 2027

  5. Results posted

    Not reported

  6. Registry updated

    Feb 25, 2026

Outcomes

What the study measures.

Primary outcomes

Complete Spontaneous Bowel Movement (CSBM) responder rate

Time frame · 8 weeks

Complete Spontaneous Bowel Movement (CSBM) responder rate is defined as the proportion of patients achieving 3 or more complete spontaneous bowel movements (CSBM) per week with an increase of 1 or more CSBM per week from baseline for at least 6 of the treatment weeks. Patient will be maintaining a daily stool diary from which data will be obtained and CSBM responder rate will be assessed.

Secondary outcomes

Mean change in weekly SBM frequency

Time frame · 8 weeks

Mean change in weekly Spontaneous Bowel Movement (SBM) after 8 weeks from baseline.

Mean change in CSBM frequency

Time frame · 8 weeks

Mean change in weekly Complete Spontaneous Bowel Movement (CSBM) after 8 weeks from baseline

Changes in weekly stool consistency measured by Bristol Stool Form Scale (BSFS)

Time frame · 8 weeks

Change in weekly stool consistency from baseline using Bristol Stool Form Scale (BSFS). The scale consists of various stool forms from type 1 to type 7. (Type 1- separate hard lumps, like nuts and hard to pass, Type 2-sausage shaped but lumpy, Type 3- Like a sausage but with cracks on the surface, Type 4- Like a sausage or snake, smooth and soft, Type 5- soft blobs with clear cut edges, Type 6- fluffy pieces ragged edges, a mushy stool, Type 7- watery, no solid pieces, entirely liquid).

Change in average weekly bloating score

Time frame · 8 weeks

Change in average weekly bloating score from baseline to week-8 using a 5-point Likert scale . Bloating means subjective abdominal fullness or distension reported by the patient. Bloating score is evaluated on a 5-point Likert scale (From 1 to 5, higher score means worse outcome)

Change in weekly straining score

Time frame · 8 weeks

Change in weekly straining score from baseline to week-8 will be measured using 5-point Likert scale (from 1 to 5, higher score means worse outcome)

Change in weekly abdominal pain or discomfort score

Time frame · 8 weeks

Change in weekly abdominal pain or discomfort score from baseline to week-8 will be measured using 5-point Likert scale (from 1 to 5, higher score means worse outcome)

Change in satisfaction score related to defecation

Time frame · 8 weeks

Satisfaction score related to defecation will be measured using 5-point defecatory satisfaction score (Likert scale, from 1 to 5, lower score means worse outcome) and change will be compared between baseline value and week-8 value.

Patient reported adverse events

Time frame · Through study completion, an average of 10 weeks

Patient-reported adverse events associated with Linaclotide treatment will be documented according to common terminology criteria for adverse events (CTCAE grading).

Sustainability of treatment effects

Time frame · 2 week of drug free follow up period (from week-9 to week-10)

Sustainability of treatment effects: Sustainability will be defined as maintenance of improved symptom scores during the 2 week drug free follow up period after week-8 at levels that are not statistically significantly worse than end of treatment values and remain no worse than baseline. These symptom scores includes weekly spontaneous bowel movement (SBM) and complete spontaneous bowel movement (CSBM) frequency, stool consistency measured by Bristol Stool Form scale (BSFS, from type 1 to 7), abdominal symptom scores including bloating score, straining score, abdominal pain or discomfort scores using 5-point Likert scale (1 to 5, higher score means worse outcome), satisfaction score related to defecation using 5-point Likert scale (1 to 5, Lower score means worse outcome) etc.

Potentially rebound of symptoms

Time frame · 2 week of drug free follow up period (from week-9 to week-10)

Rebound of symptoms: Rebound will be defined as worsening of symptom measures beyond baseline levels during the drug free follow up period. These symptom scores includes weekly spontaneous bowel movement (SBM) and complete spontaneous bowel movement (CSBM) frequency, stool consistency measured by Bristol Stool Form scale (BSFS, from type 1 to 7), abdominal symptom scores including bloating score, straining score, abdominal pain or discomfort scores using 5-point Likert scale (1 to 5, higher score means worse outcome), satisfaction score related to defecation using 5-point Likert scale (1 to 5, Lower score means worse outcome) etc.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
70 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Adult patients (18-70 years) * patients diagnosed with CIC or IBS-C based on Rome IV criteria * No abnormal finding on colonoscopy conducted within past 1 year * Patients who can read and are willing to complete daily bowel diary and follow study procedures Exclusion Criteria: * Clinical features suggestive of organic disease ( Anaemia, unexplained weight loss, per rectal bleeding, family history of malignancy) * Secondary constipation due to structural, metabolic, or neurological causes (IBD, Colorectal cancer, hypothyroidism, hypercalcemia, DM, Parkinson's disease) * History of or new onset intestinal obstruction * Prior history of stomach, small intestine and colorectal surgery ( except appendectomy or hemorroidectomy) * Patients currently suffering from medication induced costipation ( opioids, anti choline raids, calcium channel blockers, oral iron and calcium supplements, anti-Parkinsonian drug, antipsychotic, anti-emetics or psychostimulant drugs) * Use of medication affecting bowel motility ( Lubiprostone, Elobixibat, PEG or prosecretory agents) within 2 week before enrollment * Serious cardiovascular, respiratory, renal, GI, hepatic, hematological, neurological or psychiatric illness * Pregnancy or lactation

Study locations

1 registered sites.

Bangladesh. Showing up to 24 locations stored in the fast local snapshot.

Dhaka Medical College

Dhaka, Bangladesh

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Linaclotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.